Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26095784

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Jul
First author
Zhu AX

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):751-2. doi: 10.1016/S1470-2045(15)00053-4.
    note
    Source null
    related pmid
    26095780
    relationship
    Comment in

Authors and identifiers

  1. name
    Zhu AX
    type
    Author
  2. name
    Park JO
    type
    Author
  3. name
    Ryoo BY
    type
    Author
  4. name
    Yen CJ
    type
    Author
  5. name
    Poon R
    type
    Author
  6. name
    Pastorelli D
    type
    Author
  7. name
    Blanc JF
    type
    Author
  8. name
    Chung HC
    type
    Author
  9. name
    Baron AD
    type
    Author
  10. name
    Pfiffer TE
    type
    Author
  11. name
    Okusaka T
    type
    Author
  12. name
    Kubackova K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zhu AX
    type
    Author
  2. name
    Park JO
    type
    Author
  3. name
    Ryoo BY
    type
    Author
  4. name
    Yen CJ
    type
    Author
  5. name
    Poon R
    type
    Author
  6. name
    Pastorelli D
    type
    Author
  7. name
    Blanc JF
    type
    Author
  8. name
    Chung HC
    type
    Author
  9. name
    Baron AD
    type
    Author
  10. name
    Pfiffer TE
    type
    Author
  11. name
    Okusaka T
    type
    Author
  12. name
    Kubackova K
    type
    Author
bibliography ids
  1. nci-bib-67999445560fea51be4a3afd
book metadata
content sha256
dda1e182aaf0eb4b5c2d90806fb469540b9e0be47f4d1ac21e8ae43488ccaa4a
document type
citation
dois
  1. 10.1016/S1470-2045(15)00050-9
electronic publication date
display
2015 Jun 18
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26095784
immutable id
pubmed:26095784@dda1e182aaf0eb4b5c2d90806fb469540b9e0be47f4d1ac21e8ae43488ccaa4a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
859-70
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):751-2. doi: 10.1016/S1470-2045(15)00053-4.
    note
    Source null
    related pmid
    26095780
    relationship
    Comment in
outcomes validated
false
pmid
26095784
provenance
batch id
4c1ece5bfc3d8e2be622
provider
NCBI PubMed ESummary
record sha256
e0ddf9ac11a66cc605fece026cf2470cb388c07e6d8a515565a7e28e0c5071f1
response sha256
85f81bf7b60c457e4b5806b47c7c67c745ada2ae114069aa45de5ef977770dba
retrieved at
2026-09-09T23:47:12.730551+00:00
publication date
display
2015 Jul
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26095784/
title
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Preserved source evidence · Not medical advice